Testing a new antibody for pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new drug called CM313 for people with moderate to severe pemphigus, a blistering skin condition. It's for patients who haven't had this treatment before and may have not responded well to other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with pemphigus based on skin blisters, positive test results, or a skin biopsy
- You are between 18 and 80 years old
- Your pemphigus is moderate to severe, as measured by a skin score
- You have never received CM313 before, but other treatments like rituximab may not have worked well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special microscope to look at your scalp hair (trichoscopy) to see if it can help track whether your pemphigus vulgaris is active or in remission. It also checks your blood to see if the findings match your immune system's activity.
This study tests a new drug, CM313, for people with moderate to severe pemphigus (a blistering skin disease). It aims to see if the drug can help heal the blisters and sores.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This trial checks whether a simplified skin-judge score (called the Investigator Global Assessment) matches real disease severity in people with bullous pemphigoid. If your care team can score severity more easily and reliably, it may help track your response to treatment over time.
Hear when a new Pemphigus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.